This guide sets out what the SmPC actually says about Mounjaro and statins, why the two are often prescribed together, and what to discuss with your prescriber. It draws on the UK Summary of Product Characteristics and the NHS. It is general information and not a substitute for advice about your own medicines.
Can you take Mounjaro and statins together?
Yes, and it is a common combination. Many people who are overweight or have type 2 diabetes are also prescribed a statin for cardiovascular risk, so taking both is routine 3. The Mounjaro SmPC does not contraindicate statins or warn against the combination 1.
Importantly, the SmPC lists no specific interaction between tirzepatide and statins, and does not set out any special monitoring requirement for taking them together 1. So the starting point is that this is an unremarkable, commonly used combination 1.
Because some sources imply specific monitoring is needed, it is worth being clear about what the licence actually says, which the sections below do, rather than describing a requirement that is not in the corpus 1.
Is there a specific interaction?
On the evidence in the licence, no. The SmPC's interactions section does not name statins as a class requiring caution, dose changes or monitoring with tirzepatide 1. This guide does not claim an interaction that the SmPC does not describe 1.
What the SmPC does describe is a general principle: tirzepatide delays gastric emptying and can affect the rate at which oral medicines are absorbed, most noticeably at the start of treatment and after dose increases 1. But it concludes that no dose adjustments are expected for most oral medicines1.
The only medicines singled out for monitoring are narrow-therapeutic-index drugs such as warfarin and digoxin, and statins are not in that group 1. So there is no statin-specific monitoring built into the licence 1.
It is worth understanding the logic, because it explains why a confident, reassuring answer is justified rather than a vague one 1. The absorption effect the SmPC describes is about the rate at which an oral medicine is taken up, it is most pronounced when treatment starts, and for most medicines it does not change the overall exposure enough to matter 1. The drugs that get flagged are those where a small change in level could have clinical consequences, which is why warfarin and digoxin are named and most others, including statins, are not 1. So the absence of a statin warning is not an oversight; it reflects that statins do not fall into the category where the absorption effect is judged to matter 1.
What 'monitoring' actually applies
Because the question of monitoring comes up, it is worth stating plainly: the SmPC does not mandate routine monitoring for the Mounjaro-and-statin combination 1. The monitoring it advises is for narrow-therapeutic-index medicines like warfarin, where small changes in level matter, which does not include statins 1.
That does not mean your cholesterol or cardiovascular care stops being monitored; it means any such monitoring is part of your ordinary statin and cardiovascular management, not something triggered specifically by adding tirzepatide 3. Your prescriber manages that as usual 3.
The distinction is between two kinds of monitoring that are easy to conflate 1. One is interaction monitoring, checking that two medicines are not affecting each other's levels, which the SmPC reserves for narrow-therapeutic-index drugs and does not apply to statins 1. The other is the routine review of your cholesterol and cardiovascular risk that you would have anyway, statin or not 3. Adding Mounjaro does not create a new requirement of the first kind, and the second carries on exactly as before 13.
So if you have read that Mounjaro requires special statin monitoring, the accurate position from the licence is that it does not; the general absorption point applies in principle but without a statin-specific requirement 1.
This is a case where being precise actually helps, because an inflated sense of required monitoring can cause needless worry or even put people off a sensible combination 1. The honest, corpus-based message is the simpler one: there is no special test or schedule of checks that taking Mounjaro with a statin triggers 1. Your cholesterol and cardiovascular care carry on being looked after in the usual way, and adding tirzepatide does not, by itself, change that monitoring or demand a new one 13.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
Why statins and weight-loss treatment often go together
The combination is common because the same people often have both raised cardiovascular risk and excess weight. The Mounjaro licence itself recognises dyslipidaemia (abnormal blood fats) and cardiovascular disease among the weight-related conditions that can make someone eligible for treatment 1.
Statins manage cholesterol and cardiovascular risk directly, while weight-loss treatment addresses weight and its related risks, so the two target different parts of the same overall picture 13. That is why being on both is unremarkable rather than a red flag 1.
This shared cardiovascular context is also why it matters not to stop your statin simply because you are losing weight, which the next section covers 3.
It also explains why seeing both on your repeat prescription is normal rather than a sign something has gone wrong 13. The two medicines are doing different jobs at the same time: the statin works steadily on your cholesterol and cardiovascular risk, while the weight-loss treatment works on weight and the risks that come with it 1. Far from being in conflict, they are complementary parts of managing the same overall health picture, which is exactly why prescribers commonly use them side by side 13.
Cholesterol, weight loss and not stopping your statin
A practical caution: do not stop your statin on your own because you are losing weight on Mounjaro 2. Even if weight loss improves some risk factors, the decision about whether a statin is still needed belongs to the prescriber who manages your cardiovascular care, not to a self-assessment 23.
The NHS advises not stopping medicines or changing doses without advice, and that applies to statins just as it does to other treatments 2. Stopping a statin prematurely could leave cardiovascular risk untreated 2.
If you think your cholesterol or cardiovascular treatment should change as you lose weight, that is a conversation to have with your prescriber, who can review it properly 3. Weight loss and statin therapy are managed together, not traded off without advice 23.
There is a common misconception worth addressing here: that losing weight automatically makes a statin unnecessary 2. Weight loss can improve some cardiovascular risk factors, but whether a statin is still indicated depends on your overall cardiovascular risk and history, which is a clinical judgement rather than something the scales decide 23. Someone who has had a heart attack or has established cardiovascular disease, for instance, may need their statin regardless of weight change 3. So the safe stance is to let the prescriber who manages that risk make the call, and to keep taking your statin in the meantime 23.
What to discuss with your prescriber
Tell your prescriber about your statin and any other medicines before starting Mounjaro, as the NHS advises informing them of everything you take 2. This lets them confirm there is no individual concern, even though no statin-specific interaction is listed 12.
There is no special monitoring to request for the combination itself, but your ordinary cholesterol and cardiovascular reviews continue as usual 13. The key rule is to keep your statin as prescribed unless its prescriber advises a change 2.
Our guide on how Mounjaro works covers the medicine more broadly. The accurate takeaway here is that Mounjaro and statins are a common, unremarkable combination with no specific interaction or mandated monitoring in the licence 1.
If you ever do notice symptoms you associate with a statin, such as significant muscle pain, that is a matter for the prescriber who manages your statin rather than a reason to assume Mounjaro is involved, since no such interaction is described 12. Keeping the two issues separate, and raising each with the right prescriber, is the clearest way to manage being on both 23. The headline, worth holding onto, is that no statin-specific interaction or monitoring is built into the Mounjaro licence 1.
Frequently asked questions
Can you take Mounjaro and statins together?
Yes, it is a common combination, and the SmPC does not contraindicate statins or warn against taking them with tirzepatide 13. There is no specific listed interaction and no mandated special monitoring for the combination 1. Tell your prescriber all your medicines and do not stop your statin on your own 2.Is there an interaction between Mounjaro and statins?
The SmPC lists no specific interaction between tirzepatide and statins 1. The general point is that tirzepatide can affect the rate of absorption of oral medicines, but it concludes no dose adjustment is expected for most, and singles out only narrow-therapeutic-index drugs like warfarin for monitoring, not statins 1.Does Mounjaro with a statin need special monitoring?
The SmPC does not mandate special monitoring for the Mounjaro-and-statin combination 1. Any monitoring of your cholesterol or cardiovascular risk is part of your ordinary statin management, not something triggered by adding tirzepatide 3. If you have read that special monitoring is required, that is not what the licence says 1.Why are statins and Mounjaro often prescribed together?
Because the same people often have both excess weight and raised cardiovascular risk. The Mounjaro licence recognises dyslipidaemia and cardiovascular disease among the weight-related conditions relevant to treatment 1. Statins manage cholesterol directly while weight-loss treatment addresses weight, targeting different parts of the same picture 13.Can I stop my statin if I lose weight on Mounjaro?
Not on your own. Even if weight loss improves some risk factors, whether a statin is still needed is a decision for the prescriber who manages your cardiovascular care 23. The NHS advises not stopping medicines without advice, as stopping a statin prematurely could leave cardiovascular risk untreated 2.What should I tell my prescriber about my statin?
Tell them which statin and dose you take, along with any other medicines, so they can confirm there is no individual concern, even though no statin-specific interaction is listed 12. There is no special monitoring to request for the combination, and your usual cardiovascular reviews continue 13.Your next step
The Mounjaro SmPC lists no specific interaction with statins and does not mandate any special monitoring for the combination. The general point is that tirzepatide can affect the rate of oral-medicine absorption, but statins are not in the narrow-therapeutic-index group singled out for monitoring. Statins and weight-loss treatment are commonly used together for cardiovascular risk.
Tell your prescriber about your statin and all your medicines so they can confirm there is no individual concern, and keep your statin as prescribed. Do not stop it on your own because you are losing weight; whether it is still needed is a decision for the prescriber who manages your cardiovascular care. The accurate, reassuring takeaway is that this is a common, unremarkable combination with no specific interaction or mandated monitoring in the licence, so it should not be a source of worry, and your usual cardiovascular care simply continues alongside it as before.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- 4.5 Interactions (delayed gastric emptying; no adjustment for most oral medicines; only narrow-therapeutic-index drugs monitored; no statin interaction listed) and 4.1 (dyslipidaemia/CVD among weight-related comorbidities)
- Tirzepatide (tell your doctor about other medicines; do not stop medicines without advice)
- Overweight and obesity management (cardiovascular risk context; adjunct treatment)
